TRUMP ADMINISTRATION MAINTAINS MEDICARE PART D ACCESS TO HIV DRUGS

The AIDS Institute commends the decision to protect patients access to medications

Washington, DC – In reaction to today’s announcement by the Trump Administration that it would maintain existing policy for HIV drugs and not allow plans to institute prior authorization and step therapy in the Medicare Part D program, Carl Schmid, Deputy Executive Director of The AIDS Institute, issued the following statement:

“We are pleased that Secretary Azar and the Trump Administration listened to the patients and widely accepted HIV treatment guidelines by rejecting their proposal to institute prior authorization and step therapy for HIV drugs for the first time in the Medicare Part D Program. At a time when the Administration is focused on ending the HIV epidemic in the United States by increasing access to HIV drugs for treatment and prevention, allowing such bad medicine would not have made sense.”

The AIDS Institute is also pleased that the Administration is not instituting prior authorization and step therapy for patients who are already stable on their medications for people with cancer, epilepsy, mental illness, and organ transplant survivors. Many people living with and at risk of HIV experience these health conditions and we stand with them to ensure that they can access the medications that they need.”

# # #

The AIDS Institute is a national, nonpartisan, nonprofit organization that promotes action for social change through public policy, research, advocacy and education.
For more information and to become involved, visit www.TheAIDSInstitute.org or write to us at Info@theaidsinstitute.org, and follow The AIDS Institute on Twitter @AIDSAAdvocacy and Facebook at www.facebook.com/The-AIDS-Institute